FORT
MYERS, Fla., Sept. 24,
2024 /PRNewswire/ -- Clinical research findings
utilizing real-world data and conducted with participation from
Florida Cancer Specialists & Research Institute, LLC
(FCS) will be shared with a pre-eminent global audience
focused on advancing the diagnosis and treatment of multiple
myeloma, a rare blood cancer and the second most common hematologic
malignancy in the U.S. The abstract, "Perspectives of single-center
community hematologists/oncologists on minimal residual disease
testing among patients with multiple myeloma," will be presented at
the International Myeloma Society 21st Annual Meeting in
Rio De Janeiro, Brazil.
Co-authors of the abstract are Lucio N.
Gordan, MD, FCS president and managing physician,
Amanda Warner, MS, BSN, RN, OCN,
CAPM, FCS Director of Real-World Evidence, Gustavo Fonseca, MD, FACP, FCS medical
oncologist and hematologist, Trevor
Heritage, PhD, FCS senior vice president and data officer,
and Amy Ming, FCS senior director of
informatics. The research was conducted in partnership with Janssen
Scientific Affairs, LLC.
Dr. Gordan said, "Although there is no cure for multiple
myeloma, we are making steady progress to enhance the quality
of life and outcomes for patients with this disease."
"Our ability to tap real-world data derived from the treatment
FCS provides to more than one million patients, combined with
industry-leading data science, has a significant positive impact in
our understanding of blood cancers and many other diseases."
Multiple myeloma (MM) affects white plasma in the bone marrow.
Cancerous tumors can weaken the body's immune system, damage bones
and lead to end-organ damage. MM is the second most common
hematologic malignancy in the U.S. Two thirds of newly-diagnosed
patients are age 65 years or older. There is no cure; the median
age at death is 75 years.
The International Myeloma Society, a membership organization
comprised of basic research scientists, clinical investigators,
physicians and other healthcare practitioners, works to promote
research, clinical studies (including diagnosis and treatment) and
educational opportunities on all aspects of multiple myeloma
worldwide.
Abstracts presented at the IMS 2024 Conference will be published
as a special supplement to the Clinical Lymphoma, Myeloma, &
Leukemia Journal.
About Florida Cancer Specialists & Research Institute,
LLC: (FLCancer.com)
Florida Cancer Specialists & Research Institute (FCS) offers
patients access to more clinical trials than any private oncology
practice in Florida. The majority
of new cancer drugs recently approved for use in the U.S. were
studied in clinical trials with FCS participation.* Recognized for
our research, FCS is a recipient of the national Clinical Trials
Participation Award presented by the American Society of Clinical
Oncology (ASCO). FCS physicians, trained in prestigious medical
schools and research institutes, are consistently ranked nationally
as Top Doctors by U.S. News & World Report.
Celebrating its 40th year in 2024, FCS has built a
national reputation for excellence that is reflected in exceptional
and compassionate patient care, driven by innovative clinical
research, cutting-edge technologies and advanced treatments,
including targeted therapies genomic-based treatment and
immunotherapy. Our highest values are embodied by our outstanding
team of highly trained and dedicated physicians, clinicians and
staff.
*Prior to approval
View original content to download
multimedia:https://www.prnewswire.com/news-releases/florida-cancer-specialists--research-institute-real-world-evidence-capabilities-contributing-to-breakthroughs-in-blood-cancer-treatment-worldwide-302257541.html
SOURCE Florida Cancer Specialists & Research Institute